All In Biotech

Investigational drug · Phase 2

LTX-002

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "LTX-002"

First trial start

2026

Apr 29, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LTX-002", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Amyotrophic Lateral Sclerosis

Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "LTX-002" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Amyotrophic Lateral Sclerosis

  • MasitinibAB1010Phase 33 trials

    AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • PridopidinePhase 32 trials

    Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease

  • ION363Phase 31 trial

    Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis

  • MN-166ibudilastPhase 31 trial

    MediciNova · Amyotrophic Lateral Sclerosis

  • CNMAu8gold nanocrystalsPhase 22 trials

    Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis

  • AMT-162Phase 21 trial

    UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis

  • AP-101Phase 21 trial

    AL-S Pharma · Amyotrophic Lateral Sclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.